This week is bustling with innovative startups' news!
atai Life Sciences Closes $157M Series D Financing Round
atai Life Sciences, a Berlin, Germany-based clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, closed a $157m Series D financing round.
The round was led by existing investors Apeiron Investment Group, the family office of atai’s founder Christian Angermayer, Thiel Capital, and joined by Woodline Partners LP, with participation from existing and new investors including Fearless Ventures, Falcon Edge Capital, Pura Vida Pro LLC, Catalio Capital Management, Michael Auerbach’s Subversive Capital and Highline Capital.
The company intends to use the funds to expand and develop its diverse drug candidate pipeline and enabling technologies, to continue advancing its current clinical developments, as well as scale its team in order to continue delivering key milestones.
atai Life Sciences Closes $157M Series D Financing Round - FinSMEs
atai Life Sciences, a Berlin, Germany-based clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, closed a $157m Series D financing round
Exscientia Closes $100M in Series C Financing
Exscientia, an Oxford, England, UK-based clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, raised 100m in Series C funding.
Funds managed by BlackRock joined the Series C round which already included Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital. William Abecassis, Head of BlackRock’s Innovation Capital, will join Exscientia’s Board of Directors as an observer.
The company intends to use the funds for platform development towards autonomous drug design, extension of its proprietary pipeline into clinical trials and expansion of existing capabilities in biological analytics that support target selection and portfolio development.
Exscientia Closes $100M in Series C Financing - FinSMEs
Exscientia, an Oxford, England, UK-based clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, raised 100m in Series C funding
Danish insect pheromone startup BioPhero lands €14.2 million to replace chemical insecticides
Today BioPhero, the insect pheromone company, today announced it has raised around €14.2 million in Series A funding led by DCVC Bio with participation from new investor FMC Ventures, as well as existing investors Syngenta Group Ventures and Novo Holdings.
The startup, which has a mission to replace many chemical insecticides with sustainable biological insect pheromones, will use this funding to ramp up production of several products and to produce pheromones at the quantity, quality, and price required to allow farmers to control major pests in a variety of row crops.
Danish insect pheromone startup BioPhero lands €14.2 million to replace chemical insecticides | EU-Startups
Today BioPhero, the insect pheromone company, today announced it has raised around €14.2 million in Series A funding led by DCVC Bio with participation
CVasThera Secures €1.3M in Funding Round
CVasThera, a Toulouse, France-based biopharmaceutical company that specializes in the development of novel therapies for cardiovascular and bowel pathologies, secured €1.3m ($1.6M) in first funding.
The round was led by OCSEED, a venture capital company supporting startups in the Occitanie region of France via convertible bonds, supported by an investment loan from Bpifrance, the Occitanie region and a contract with the Agence Nationale de la Recherche, the French National Research Agency.
The company intends to use the funds for clinical stage trials, recruitment of additional team members and support of its pharmaceutical research and development work.
CVasThera Secures €1.3M in Funding Round - FinSMEs
CVasThera, a Toulouse, France-based biopharmaceutical company that specializes in the development of novel therapies for cardiovascular and bowel pathologies, secured €1.3m ($1.6M) in first funding
DispatchHealth Raises $200M in Series D Financing
DispatchHealth, a Denver, CO-based provider of in-home medical care, secured an additional $200m in Series D financing.
The round, which brought total funding to more than $417m and raised its valuation to $1.7 billion, was led by Tiger Global with participation from previous investors Alta Partners, Echo Health Ventures, Humana, Oak HC/FT and Questa Capital.
The company intends to use the funds to expand its platform for in-home medical care to a total of 100 markets and its Advanced Care line of service across the United States.
DispatchHealth Raises $200M in Series D Financing - FinSMEs
DispatchHealth, a Denver, CO-based provider of in-home medical care, secured an additional $200m in Series D financing
Century Therapeutics Closes $160M Series C Financing
Century Therapeutics, a Philadelphia, PA-based cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, closed a $160m Series C financing.
The round was led by Casdin Capital and brought together a syndicate of new investors including Fidelity Management & Research LLC, the Federated Hermes Kauffmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital. Founding investors Versant Ventures and Leaps by Bayer also participated. Eli Casdin, Founder and Chief Investment Officer of Casdin Capital will be joining the Century Therapeutics Board of Directors.
Led by Lalo Flores, Chief Executive Officer, Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer. Its genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers.
The company intends to use the funds to advance its rich pre-clinical pipeline, which includes multiple iPSC-derived CAR-iT and CAR-iNK cell products. These products are designed to resist host rejection, enhance cell persistence, and allow repeat dosing to provide durable responses in all patients.
Century Therapeutics Closes $160M Series C Financing - FinSMEs
Century Therapeutics, a Philadelphia, PA-based cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, closed a $160m Series C financing
eGenesis Raises $125M in Series C Financing
eGenesis, a Cambridge, Mass.-based gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, completed a $125m Series C financing.
Backers included Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus, Samsara BioCapital, LifeSci Venture Partners, and more such as Fresenius Medical Care Ventures.
The company intends to use the funds to bring its lead programs in kidney and islet cell transplant into human proof-of-concept studies and continue to develop its proprietary gene-editing platform and scaling of GMP production.
Led by Paul Sekhri, President and Chief Executive Officer, eGenesis aims to offer safe and effective organs, tissues, and cells to patients in need.
eGenesis Raises $125M in Series C Financing - FinSMEs
eGenesis, a Cambridge, Mass.-based gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, completed a $125m Series C financing
Amunix Raises $117M in Series B Financing
Amunix Pharmaceuticals, Inc., a South San Francisco, CA-based biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, raised $117m in Series B financing.
The round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton and more.
The company intends to use the funds for the advancement into the clinic of AMX-818, a masked, protease-activated T cell engager (XPAT®) targeting HER2-expressing solid tumors, as well as support Amunix’s robust pipeline of earlier stage XPATs® and masked, protease-activated cytokines (XPACs™).
Amunix Raises $117M in Series B Financing - FinSMEs
Amunix Pharmaceuticals, Inc., a South San Francisco, CA-based biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, raised $117m in Series B financing
Caribou Biosciences Raises $115M in Series C Funding
Caribou Biosciences, Inc., a Berkeley, Calif.-based clinical-stage CRISPR genome editing biotechnology company, closed a $115m Series C financing.
The round was co-led by new premier healthcare investors Farallon Capital Management, PFM Health Sciences, and Ridgeback Capital Investments
The company intends to use the funds for further develop its proprietary, next-generation CRISPR technology platform and to advance its pipeline of wholly-owned allogeneic immune cell therapies for oncology with best-in-class potential.
Led by Jennifer Doudna, Ph.D., co-founder, and Rachel Haurwitz, Ph.D., President and Chief Executive Officer, Caribou has developed a next-generation CRISPR technology platform which has advanced a pipeline of allogeneic cell therapies for oncology.
Caribou Biosciences Raises $115M in Series C Funding - FinSMEs
Caribou Biosciences, Inc., a Berkeley, Calif.-based clinical-stage CRISPR genome editing biotechnology company, closed a $115m Series C financing
DTx Pharma Closes $100M Series B Financing
DTx Pharma, Inc., a San Diego, CA-based biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, completed a $100m Series B financing.
The round was led by RA Capital Management with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital and existing investors.
The company intends to use the funds to utilize its FALCON fatty acid motifs to advance assets into clinical development across several therapeutic areas over the next few years.
Led by Arthur T. Suckow, Ph.D., chief executive officer, and Denise Bevers, chief operating officer, DTx Pharma is a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease.
DTx Pharma Closes $100M Series B Financing - FinSMEs
DTx Pharma, Inc., a San Diego, CA-based biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, completed a $100m Series B financing
CorVista Health Closes $65M Series C Equity Funding
CorVista Health, Inc., a Toronto, CA-based digital health company dedicated to improving cardiovascular disease diagnosis, closed a $65m Series C equity financing.
This round, which brought the total amount raised to nearly $100, was led by Ambix Life Science Fund I, L.P., joined by MedVenture Partners, Inc. as well as several new and previous investors.
Additionally, ongoing clinical research is being accelerated for the CorVista System to assess for coronary artery disease as well as elevated left ventricular end diastolic pressure and elevated mean pulmonary artery pressure, hallmarks of heart failure and pulmonary hypertension, respectively.
The company intends to use the funds accelerate product development for the CorVista System and scale its infrastructure ahead of commercialization
Led by Don Crawford, Chief Executive Officer, CorVista System provides a non-invasive, point-of-care solution that allows physicians to rapidly test for heart disease.
